These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 38430402

  • 1. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).
    Oh SJ, Cho ST, Kuo HC, Chou EC, Hsu YC, Lee KS, Hadi F, Song Y, Sumarsono B.
    Adv Ther; 2024 Apr; 41(4):1652-1671. PubMed ID: 38430402
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K.
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [Abstract] [Full Text] [Related]

  • 3. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A.
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [Abstract] [Full Text] [Related]

  • 4. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
    Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR.
    Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
    [Abstract] [Full Text] [Related]

  • 5. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E.
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [Abstract] [Full Text] [Related]

  • 6. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.
    Rovner ES, Carlson KV, Deal AS, Nair KV, Oakkar EE, Park J, Gemmen E, Kristy RM, Gooch KL, Schermer CR.
    Contemp Clin Trials; 2018 Jul; 70():83-87. PubMed ID: 29777865
    [Abstract] [Full Text] [Related]

  • 7. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
    Nazir J, Hakimi Z, Guelfucci F, Khemiri A, Fatoye F, Blázquez AMM, González MH.
    BMC Urol; 2018 Sep 04; 18(1):76. PubMed ID: 30180826
    [Abstract] [Full Text] [Related]

  • 8. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A.
    Eur Urol; 2015 Mar 04; 67(3):577-88. PubMed ID: 24612659
    [Abstract] [Full Text] [Related]

  • 9. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study.
    Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC.
    Low Urin Tract Symptoms; 2021 Oct 04; 13(4):425-434. PubMed ID: 33987973
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z.
    Eur Urol; 2014 Apr 04; 65(4):755-65. PubMed ID: 24275310
    [Abstract] [Full Text] [Related]

  • 11. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB.
    J Manag Care Spec Pharm; 2016 Sep 04; 22(9):1072-84. PubMed ID: 27579830
    [Abstract] [Full Text] [Related]

  • 12. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M, Nukui A, Kamai T.
    Low Urin Tract Symptoms; 2018 May 04; 10(2):158-166. PubMed ID: 28009939
    [Abstract] [Full Text] [Related]

  • 13. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.
    Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F.
    BMJ Open; 2018 Nov 21; 8(11):e021889. PubMed ID: 30467131
    [Abstract] [Full Text] [Related]

  • 14. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL, Chen TC, Chang HM, Juan YS, Huang WH, Pan HF, Chang YC, Wu CM, Wang YL, Lee HY.
    World J Urol; 2018 Aug 21; 36(8):1285-1297. PubMed ID: 29556972
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, Nazir J, Chapple C.
    Eur Urol; 2018 Sep 21; 74(3):324-333. PubMed ID: 29699858
    [Abstract] [Full Text] [Related]

  • 16. A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
    Milsom I, Schiotz HA, Svensson M, Kilany S, Hansson F.
    Scand J Urol; 2019 Aug 21; 53(4):246-254. PubMed ID: 31195868
    [Abstract] [Full Text] [Related]

  • 17. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
    Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K.
    Low Urin Tract Symptoms; 2018 May 21; 10(2):148-152. PubMed ID: 27911988
    [Abstract] [Full Text] [Related]

  • 18. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
    Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T.
    Curr Med Res Opin; 2016 May 21; 32(4):621-38. PubMed ID: 26828974
    [Abstract] [Full Text] [Related]

  • 19. [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
    Krunal Vishavadia KV, Sandip Solanki SS, Hiren Prajapati HP, Madhu Sharma MS.
    Urologiia; 2023 May 21; (2):66-72. PubMed ID: 37401707
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stölzel M, Herholdt C, MacDiarmid S, BESIDE study investigators.
    Eur Urol; 2016 Jul 21; 70(1):136-145. PubMed ID: 26965560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.